MBIO Stock Summary and Trading Ideas (Mustang Bio | NASDAQ:MBIO)

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Mustang Bio trades on the NASDAQ stock market under the symbol MBIO.

As of April 19, 2024, MBIO stock price declined to $0.34 with 127,709 million shares trading.

MBIO has a beta of 2.99, meaning it tends to be more sensitive to market movements. MBIO has a correlation of 0.13 to the broad based SPY ETF.

MBIO has a market cap of $3.55 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, MBIO stock traded as high as $60.90 and as low as $.33.

The top ETF exchange traded funds that MBIO belongs to (by Net Assets): VTI, VXF, IWC, FESM.

MBIO has underperformed the market in the last year with a price return of -91.1% while the SPY ETF gained +21.2%. MBIO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -75.4% and -56.5%, respectively, while the SPY returned +4.3% and -3.5%, respectively.

MBIO support price is $.33 and resistance is $.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MBIO stock will trade within this expected range on the day.